Node-negative breast cancer: identifying those who should be spared adjuvant therapy
Oncology 4(12): 15-16
1990
ISSN/ISBN: 0890-9091 PMID: 2149033 Document Number: 367529
Document emailed within 1 workday
Related Documents
Roumen, R.M. 2000: Prognostic benefits evaluated: new guidelines for systemic adjuvant therapy for axillary node-negative breast cancer vs. implementation of sentinel node biopsy procedure Nederlands Tijdschrift Voor Geneeskunde 144(21): 980-984Mathoulin-Portier, M.P.; Meynard, P.; Charton-Bain, M.C.; Escoute, M.; Bardou, V.J.; Puig, B.; Viens, P.; Cowen, D.; Houvenaeghel, G.; Hassoun, J.; Jacquemier, J. 1999: Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy Anticancer Research 19(1b): 843-847
Merkel, D.E.; Osborne, C.K. 1989: Adjuvant treatment of node-negative breast cancer Texas Medicine 85(1): 32-36
Sutepvarnon, A.; Warnnissorn, M.; Srimuninnimit, V. 2013: Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer Journal of the Medical Association of Thailand 96(Suppl 2): S60-S66
Yamamoto, N.; Tabei, T.; Inoue, K.; Takei, H.; Sato, N.; Yanagita, Y.; Fujisawa, T.; Fujii, H.; Saeki, T.; Kurosumi, M. 2010: Tolerability and safety of docetaxel plus cyclophosphamide as adjuvant chemotherapy for axillary lymph node-negative breast cancer--JECBC04 trial Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(1): 57-63
Abe, R.; Tsuchiya, A.; Koie, H.; Ono, K.; Abo, S.; Saito, K.; Tsukamoto, M.; Sato, T.; Mori, S.; Motoki, R. 1988: Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(9): 2707-2712
Dent, D.M.; Hacking, E.A.; Gudgeon, C.A. 1989: Adjuvant therapy after surgery for breast cancer--should women without axillary node involvement be candidates South African Medical Journal 75(11): 513-514
Folli, S.; Falco, G.; Mingozzi, M.; Buggi, F.; Curcio, A.; Ferrari, G.; Taffurelli, M.; Regolo, L.; Nanni, O. 2016: Repeat sentinel lymph node biopsy in patients with ipsilateral recurrent breast cancer after breast-conserving therapy and negative sentinel lymph node biopsy: a prospective study Minerva Chirurgica 71(2): 73-79
Wang, Y.; Yao, L.; Liu, Y.-q.; Xu, Y.; Ou, Y.-t.; Li, J.-f.; Wang, T.-f.; Fan, Z.-q.; Fan, T.; Lin, B.-y.; Xie, Y.-t. 2010: Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer Zhonghua Zhong Liu Za Zhi 32(7): 511-514
Kohlberger, P.; Gantert, M.; Volk-Orlowska, T.; Kieback, D.G.; Gitsch, G. 2001: Immunohistochemical detection of lymph node metastases in node-negative breast cancer patients Anticancer Research 21(1b): 697-699
Karalak, A.; Homcha-Em, P. 1999: Occult axillary lymph node metastases discovered by serial section in node-negative breast cancer Journal of the Medical Association of Thailand 82(10): 1017-1019
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. I. Prognostic factors in patients with node-negative (N0) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 159-163
Yoshida, M.; Saji, S.; Takagi, H.; Takeuchi, S.; Tsuda, H.; Nimura, Y.; Mizumoto, R.; Miyazaki, I.; Kobayashi, S.; Noguchi, M. 1993: A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. the Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(15): 2325-2333
Tuipae, S.; Yanaranop, M.; Oniem, N. 2012: Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors Journal of the Medical Association of Thailand 95(Suppl 3): S117-S124
Saito, A.I.; Karasawa, K. 2007: Adjuvant radiotherapy for the lymph node area of breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 6): 479-483
Salvadori, B.; Celio, L.; Oriana, R.; Bajetta, E. 2000: Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: long-term results of an experience at the Milan Cancer Institute Tumori 86(3): 258-259
Castiglione-Gertsch, M.; Tattersall, M.; Hacking, A.; Goldhirsch, A.; Gudgeon, A.; Gelber, R.D.; Lindtner, J.; Coates, A.; Collins, J.; Isley, M.; Senn, H.J.; Rudenstam, C.M. 1997: Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group European Journal of Cancer 33(14): 2321-2325
Buchholz, T.A.; Hunt, K.K.; Amosson, C.M.; Tucker, S.L.; Strom, E.A.; McNeese, M.D.; Buzdar, A.U.; Singletary, S.E.; Hortobagyi, G.N. 1999: Sequencing of chemotherapy and radiation in lymph node-negative breast cancer Cancer Journal From Scientific American 5(3): 159-164
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Gasparini, G.; Bevilacqua, P.; Dal Fior, S.; Panizzoni, G.A.; Favretto, S.; Visonà, A.; Meli, S. 1990: Characterization of node-negative breast cancer by clinico-pathologic and biologic factors Anticancer Research 10(1): 205-208